Jazz Reports Phase 3 Success for Ziihera in HER2+ GEA
DUBLIN, Ireland, May 27, 2026 Jazz Pharmaceuticals has announced the publication of pivotal Phase 3 HERIZON-GEA-01 trial results in...
AI drug discovery Alzheimer’s Disease artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
DUBLIN, Ireland, May 27, 2026 Jazz Pharmaceuticals has announced the publication of pivotal Phase 3 HERIZON-GEA-01 trial results in...
HERZLIYA, Israel and CALGARY, Alberta, May 27, 2026 Innocan Pharma Corporation has reported strong first-quarter 2026 financial results, highlighting...
LONDON, United Kingdom – May 6, 2026 Calla Lily Clinical Care has announced dosing of the first patients in...
